Pancreatic Cancer Research

ResearcherMichael E. DeBakey VA Medical CenterActive in the last 2 years

Qizhi Cathy Yao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2267-0588; OpenAlex author ID A5038846608; NIH RePORTER profile ID 6605418. Sources: OpenAlex.

Their work

Papers
19 (first author 0, last author 8)
Trials
0
Grants
4
Labs led
2
Collaborators
48
Papers, trials and grants by year

2011: 5 papers · 2012: none · 2013: 4 papers · 2014: none · 2015: none · 2016: 2 papers · 2017: none · 2018: none · 2019: 1 paper, 1 grant · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper, 1 grant · 2025: 2 papers, 1 grant · 2026: none · 2027: 1 grant

Papers 19

  1. Oncolytic adeno-immunotherapy improves allogeneic adoptive HER2.CAR-NK function against pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.omton.2025.201006↗
  2. Mesothelin-Associated Anti-Senescence Through P53 in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers17122058↗
  3. Proteome-wide association study and functional validation identify novel protein markers for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/gigascience/giae012↗
  4. XDec-CHI reveals immunosuppressive interactions in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2022.105249↗
  5. A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic ductal adenocarcinoma. Co-author DOI 10.1126/scitranslmed.abc3196↗
  6. Histoepigenetic analysis of the mesothelin network within pancreatic ductal adenocarcinoma cells reveals regulation of retinoic acid receptor gamma and AKT by … Co-author DOI 10.1038/s41389-020-00245-3↗
  7. A Transcriptome-Wide Association Study Identifies Candidate Susceptibility Genes for Pancreatic Cancer Risk. Co-author DOI 10.1158/0008-5472.can-20-1353↗
  8. Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib. Last author DOI 10.1371/journal.pone.0213294↗
  9. Chemo-immunotherapy mediates durable cure of orthotopic KrasG12D/p53-/- pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2016.1213933↗
  10. Overexpression of Semaphorin-3E enhances pancreatic cancer cell growth and associates with poor patient survival. Last author DOI 10.18632/oncotarget.13704↗
  11. A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth. Co-author DOI 10.1002/emmm.201302507↗
  12. A tumorigenic factor interactome connected through tumor suppressor microRNA-198 in human pancreatic cancer. Last author DOI 10.1158/1078-0432.ccr-12-3776↗
  13. Mesothelin virus-like particle immunization controls pancreatic cancer growth through CD8+ T cell induction and reduction in the frequency of CD4+ foxp3+ ICOS-… Last author DOI 10.1371/journal.pone.0068303↗
  14. Gene profile identifies zinc transporters differentially expressed in normal human organs and human pancreatic cancer. Co-author DOI 10.2174/1566524011313030009↗
  15. Roles and mechanisms of microRNAs in pancreatic cancer. Co-author DOI 10.1007/s00268-010-0952-z↗
  16. Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Last author DOI 10.1093/carcin/bgr075↗
  17. Chimeric Trop2 virus-like particles: a potential immunotherapeutic approach against pancreatic cancer. Last author DOI 10.1097/cji.0b013e318209ee72↗
  18. Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression. Last author DOI 10.1186/1476-4598-10-106↗
  19. Overcoming drug resistance in pancreatic cancer. Co-author DOI 10.1517/14728222.2011.566216↗

Grants 4

  1. Novel Pathogenic Roles and Mechanisms of Fibrinogen in Pancreatic Cancer I01BX005806↗
  2. BLR&D Research Career Scientist Award Application IK6BX007143↗
  3. Stratification of Pancreatic Cancer Subpopulations for Effective Immunotherapy I01CX001822↗
  4. A novel miR-198 replacement therapy for pancreatic cancer R01CA183984↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Changyi Chen · 11 shared papers, 2011–2025 · strength 0.87
  2. Dongliang Liu · 4 shared papers, 2019–2025 · strength 0.72
  3. Aleksandar Milosavljevic · 2 shared papers, 2020–2022 · strength 0.34
  4. Emily L. LaPlante · 2 shared papers, 2020–2022 · strength 0.34
  5. Dalia H. Ghoneim · 2 shared papers, 2020–2024 · strength 0.27
  6. Lang Wu · 2 shared papers, 2020–2024 · strength 0.27
  7. Jingjing Zhu · 2 shared papers, 2020–2024 · strength 0.27
  8. Ryu Matsumoto · 1 shared paper, 2025 · strength 0.24
  9. Greyson W. G. Biegert · 1 shared paper, 2025 · strength 0.24
  10. Masataka Suzuki · 1 shared paper, 2025 · strength 0.24
  11. Ethan C. Poteet · 2 shared papers, 2016–2019 · strength 0.17
  12. George Van Buren · 2 shared papers, 2016–2019 · strength 0.17
  13. Tanxin Liu · 1 shared paper, 2024 · strength 0.16
  14. Tao Liu · 1 shared paper, 2024 · strength 0.16
  15. Youping Deng · 1 shared paper, 2024 · strength 0.16
  16. Hua Zhong · 1 shared paper, 2024 · strength 0.16
  17. Shuai Liu · 1 shared paper, 2024 · strength 0.16
  18. Vanaja Konduri · 2 shared papers, 2016–2021 · strength 0.16
  19. William Karl Decker · 2 shared papers, 2016–2021 · strength 0.16
  20. William E. Fisher · 4 shared papers, 2013–2016 · strength 0.15
  21. Eugene Lurie · 1 shared paper, 2020 · strength 0.13
  22. Duo Liu · 1 shared paper, 2020 · strength 0.11
  23. Eric R. Gamazon · 1 shared paper, 2020 · strength 0.11
  24. Christian Marín‐Müller · 3 shared papers, 2011–2013 · strength 0.10
  25. Uddalak Bharadwaj · 3 shared papers, 2011–2013 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.